**SPRINT**

**Trial design:** Patients with systolic BP \(\geq\)130 mm Hg and at least one risk factor were randomized in a 1:1 fashion to either intensive SBP lowering (target \(<\)120 mm Hg) or routine SBP management (target \(<\)140 mm Hg). Patients were followed for 5 years.

**Results**
- Primary outcome, MI/ACS/stroke/CHF/CV death: intensive vs. routine: 1.65%/year vs. 2.19%/year, HR 0.75, 95% CI 0.64-0.89; \(p < 0.0001\); stroke: 1.3% vs. 1.5%, \(p = 0.5\); CHF: 1.3% vs. 2.1%, \(p = 0.002\)
- Mortality: 3.3% vs. 4.5%, \(p = 0.0003\); CV death: 0.8% vs. 1.4%, \(p = 0.0005\); worsening renal function among patients without CKD: 3.8% vs. 1.1%, \(p < 0.001\)
- Hypotension: 2.4% vs. 1.4%, \(p = 0.001\)

**Conclusions**
- Landmark trial; indicates that intensive BP lowering to a target \(<\)120 mm Hg is superior to routine management with a target of \(<\)140 mm Hg in non-diabetic patients with HTN, including in elderly patients. Reductions were also noted in CV and all-cause mortality, accompanied by a reduction in CHF
- Likely to impact clinical practice and guidelines

**www.acc.org**